All stages of the HCV life cycle are potential targets, however targeting the HCV NS3–4A serine protease, NS5A and the NS5B RNA-dependent RNA polymerase are most clinically advanced. DAAs ...

Global Phase 3 HCV Program Expected to Initiate in 1Q 2025Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports ...

but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor; (genotype 3): treat for 16 weeks if previously treated with regimens containing PEG-IFN, ribavirin, and/or ...